Core Viewpoint - The company, Plater (688333.SH), is involved in the development of the "Gravity One" rocket by providing components, specifically printing main bundle-related parts for the client [1]. Group 1 - The company confirmed its participation in the "Gravity One" rocket's research and development [1]. - The company has printed relevant components for the main bundle of the rocket [1]. - Further information will be released on January 12, 2024, via the company's official WeChat account "Metal 3D Printing Expert Plater" [1].

Core Viewpoint - Suzhou Su Da Wei Ge Technology Group Co., Ltd. has experienced a stock price fluctuation, with a year-to-date increase of 49.56% but a recent decline of 8.92% over the last five trading days [1] Group 1: Stock Performance - As of October 16, the stock price of Su Da Wei Ge is 32.35 CNY per share, with a market capitalization of 8.4 billion CNY [1] - The stock has seen a trading volume of 264 million CNY and a turnover rate of 3.81% [1] - The company has appeared on the "Dragon and Tiger List" twice this year, with the latest appearance on September 5, where it recorded a net purchase of 112 million CNY [1] Group 2: Financial Performance - For the first half of 2025, Su Da Wei Ge reported a revenue of 982 million CNY, representing a year-on-year growth of 5.27% [2] - The net profit attributable to shareholders for the same period was 30.66 million CNY, showing a year-on-year decrease of 10.46% [2] Group 3: Shareholder Information - As of June 30, 2025, the number of shareholders increased by 13.86% to 30,700, while the average circulating shares per person decreased by 10.45% to 6,855 shares [2] - The company has distributed a total of 108 million CNY in dividends since its A-share listing, with no dividends paid in the last three years [3] - The third-largest circulating shareholder is Ruiyuan Growth Value Mixed A, holding 12.41 million shares, a decrease of 261,800 shares from the previous period [3]

Core Points - The stock price of Huaxiang Co., Ltd. dropped by 2.00% on October 16, trading at 16.62 yuan per share with a market capitalization of 8.961 billion yuan [1] - The company has seen a year-to-date stock price increase of 34.22%, but has experienced declines of 5.30% over the last five trading days, 4.92% over the last twenty days, and 11.60% over the last sixty days [1] - As of June 30, 2025, Huaxiang Co., Ltd. reported a revenue of 1.976 billion yuan, a year-on-year increase of 2.38%, and a net profit attributable to shareholders of 290 million yuan, reflecting a year-on-year growth of 25.66% [2] Financial Performance - The company has distributed a total of 599 million yuan in dividends since its A-share listing, with 426 million yuan distributed over the past three years [3] - As of June 30, 2025, the number of shareholders increased to 13,800, with an average of 36,628 circulating shares per shareholder, marking a 15.01% increase from the previous period [2] Shareholder Structure - The top ten circulating shareholders include XINGQUAN HEYUAN Two-Year Holding Mixed A, which holds 3.2844 million shares, a decrease of 122,400 shares from the previous period [3] - Hong Kong Central Clearing Limited is the tenth largest circulating shareholder, holding 2.4365 million shares, an increase of 111,770 shares from the previous period [3]

Core Viewpoint - Nanfeng Co., Ltd. (300004.SZ) is actively engaging in business discussions and sample deliveries with relevant clients for its 3D printing products, including liquid cooling plates [1] Company Summary - Nanfeng Co., Ltd. is involved in the production of 3D printing products, specifically highlighting its capability to manufacture liquid cooling plates [1]

Core Viewpoint - Apple-related stocks have generally risen following a meeting between Apple's CEO Tim Cook and China's Minister of Industry and Information Technology, Li Lecheng, discussing Apple's business development in China and cooperation in the electronic information sector [1] Group 1: Stock Performance - Hongteng Precision (06088) increased by 4.23%, trading at 5.92 HKD [1] - Sunny Optical (02382) rose by 3.44%, trading at 79.7 HKD [1] - Q Technology (01478) saw a 3.29% increase, trading at 15.09 HKD [1] - Lens Technology (300433) (06613) gained 2.15%, trading at 26.56 HKD [1] Group 2: Business Development and Cooperation - Tim Cook expressed gratitude for the support from the Ministry of Industry and Information Technology regarding Apple's development in China and committed to increasing investments in the region [1] - The discussion included enhancing cooperation in the electronic information field to achieve mutually beneficial development [1] Group 3: Industry Insights - Huafu Securities noted that the impact of tariffs on Apple’s supply chain equipment companies should not be overestimated, emphasizing the strict requirements Apple places on its suppliers [1] - Domestic supply chain companies are deemed irreplaceable, and Apple may allocate more resources towards cost-reducing and efficiency-enhancing technologies such as flexible automation and 3D printing [1] - There is potential for accelerated promotion of high-end models, foldable screens, and smart glasses, which would benefit the establishment and upgrading of related production lines [1]

Core Viewpoint - Apple-related stocks have generally risen following a meeting between Apple's CEO Tim Cook and China's Minister of Industry and Information Technology, Li Lecheng, where they discussed Apple's business development in China and cooperation in the electronic information sector [1] Group 1: Stock Performance - Hongteng Precision (06088) increased by 4.23%, trading at HKD 5.92 [1] - Sunny Optical Technology (02382) rose by 3.44%, trading at HKD 79.7 [1] - Q Technology (01478) saw a 3.29% increase, trading at HKD 15.09 [1] - Lens Technology (06613) gained 2.15%, trading at HKD 26.56 [1] Group 2: Business Development and Cooperation - Tim Cook expressed gratitude for the support from the Ministry of Industry and Information Technology regarding Apple's development in China and indicated plans to increase investment in the region [1] - The discussion focused on enhancing cooperation in the electronic information field to achieve mutually beneficial development [1] Group 3: Industry Insights - Huafu Securities noted that the impact of tariffs on Apple’s supply chain equipment companies should not be overestimated, as Apple has strict requirements for its suppliers [1] - Domestic supply chain companies are deemed irreplaceable, and Apple may allocate more resources towards flexible automation, 3D printing, and new technologies to reduce costs and improve efficiency [1] - There is potential for accelerated promotion of high-end models, foldable screens, and smart glasses, which would benefit the establishment and upgrading of related production lines [1]

Core Insights - Koli Electric Group's stock price increased by 2.06% to 13.90 CNY per share, with a total market capitalization of 10.338 billion CNY as of October 15 [1] - The company reported a year-to-date stock price increase of 8.66%, but a decline of 5.95% over the last five trading days [1] - Koli Electric's main business segments include smart home products (74.25%), motion control products (13.02%), and health and care products (11.06%) [1][2] Financial Performance - For the first half of 2025, Koli Electric achieved a revenue of 907 million CNY, representing a year-on-year growth of 13.91% [2] - The net profit attributable to shareholders for the same period was 29.1764 million CNY, reflecting a growth of 23.31% year-on-year [2] - Cumulative cash dividends since the company's A-share listing amount to 351 million CNY, with 125 million CNY distributed over the last three years [3] Shareholder Structure - As of June 30, 2025, the number of Koli Electric shareholders decreased by 3.03% to 76,700, while the average number of circulating shares per person increased by 25.76% to 6,303 shares [2] - Notable institutional shareholders include Huaxia CSI Robot ETF, which increased its holdings by 1.459 million shares, and new entrants like Southern CSI 1000 ETF [3]

Core Viewpoint - Spring Medical, a leading domestic orthopedic medical device manufacturer, is focusing on the research, production, and sales of implantable orthopedic medical devices, including dental metal and invisible orthodontics, and is currently in the design and inspection phase for customized dental implants [2][3]. Company Overview - Spring Medical is located in Tongzhou District, Beijing, and was established on February 12, 1998. The company specializes in the research, production, and sales of implantable orthopedic medical devices, with its main products including joint prosthetics and spinal implants [7][8]. - The company's main product categories include joint prosthetics covering hip, knee, shoulder, and elbow joints, as well as a full range of spinal internal fixation systems [5][8]. Financial Performance - For the first half of 2025, Spring Medical achieved operating revenue of 488 million yuan, representing a year-on-year growth of 28.27%, and a net profit attributable to shareholders of 114 million yuan, up 44.85% year-on-year [8]. - Since its A-share listing, the company has distributed a total of 359 million yuan in dividends, with 309 million yuan distributed over the past three years [8]. Industry Position - Spring Medical has been recognized as a "specialized, refined, distinctive, and innovative" small giant enterprise, which is a prestigious title in the national evaluation of small and medium-sized enterprises, indicating its strong market position and innovation capabilities [3]. - The company has introduced various types of 3D printing equipment for the development of customized prosthetic products, including EBM and MJF technologies, enhancing its production capabilities [2][3]. Market Activity - On October 14, Spring Medical's stock price decreased by 0.74%, with a trading volume of 35.81 million yuan and a turnover rate of 0.54%, bringing the total market capitalization to 8.73 billion yuan [1]. - The stock has seen a net outflow of 527,000 yuan from major funds today, with a continuous reduction in major fund holdings over the past three days [4][5].

Core Viewpoint - The company's revenue growth in H1 2025 is under short-term pressure, while profit growth meets expectations. Looking ahead to H2 2025, the nationwide implementation of the artificial joint procurement renewal policy is expected to stabilize the industry pricing system. The company has seen price increases in hip and knee joint bids during this renewal, indicating a potential for both volume and price growth. The orthopedic surgery volume is expected to recover, and with a low revenue base from the previous year, the company is projected to experience a trend of lower performance in the first half and higher performance in the second half of the year. In the medium to long term, the company's forward-looking layout in 3D printing, surgical robots, and digital orthopedic ecosystems will create solid technological barriers and open new growth spaces. Additionally, the overseas market is expected to become a strong growth engine as the "JRI + Aikang" dual-brand strategy deepens and product registrations continue to progress [1][2][3]. Financial Performance - In H1 2025, the company achieved a revenue of 694 million yuan, a year-on-year increase of 5.6%, and a net profit of 161 million yuan, a year-on-year increase of 15.3%. The earnings per share (EPS) was 0.14 yuan. The revenue growth was driven by accelerated import substitution due to volume-based procurement policies, leading to increased sales of products within the procurement scope. The company made breakthroughs in clinical applications at high-end medical institutions, particularly in key provinces such as Shanghai, Guangdong, and Zhejiang [1][2][3]. Product Performance - By product, the company reported hip joint revenue of 410 million yuan (up 14.0% year-on-year), knee joint revenue of 194 million yuan (down 0.7% year-on-year), primarily due to price declines in single condyle products outside the procurement scope, and spinal and trauma revenue of 51 million yuan (down 26.5% year-on-year) due to policy impacts. Revenue from digital orthopedic customized products and services was 18 million yuan (up 3.9% year-on-year). The K3 intelligent surgical robot, developed in-house, was approved for market launch in May 2025, with over 1,700 clinical surgeries completed using the intelligent assistance devices [2][3]. Market Outlook - The comprehensive execution of the artificial joint procurement renewal policy is expected to accelerate performance in the second half of the year. The company is steadily increasing its market share due to its cost-effectiveness and localized service advantages, which are accelerating import substitution and coverage in high-end hospitals. The iCOS digital orthopedic platform provides a full-process solution from preoperative planning to intraoperative navigation and postoperative monitoring. With the approval of the K3 intelligent surgical robot, digital products and implants are expected to see collaborative growth. The international market is viewed as the second growth curve for the company, with the dual-brand strategy effectively covering different overseas markets and gradually increasing the proportion of overseas revenue, indicating significant growth potential [2][3]. Financial Metrics - The company's gross margin for H1 2025 was 59.1%, a decrease of 1.5 percentage points year-on-year, primarily due to changes in product structure, with a decline in the revenue share of spinal and trauma implants. The company maintained good expense control, with a sales expense ratio of 16.9% (down 0.2 percentage points year-on-year) and a management expense ratio of 11.2% (up 0.2 percentage points year-on-year). The R&D expense ratio remained stable at 9.6%, reflecting ongoing investment to maintain technological leadership. As of June 30, 2025, the company's net current assets were approximately 1.846 billion yuan, an increase of about 264 million yuan compared to the end of 2024, mainly due to improvements in operational performance [3]. Profit Forecast - In the short term, the volume and price growth effects from the artificial joint procurement renewal are expected to manifest, driving high growth in the business for the second half of the year. In the medium to long term, the company's forward-looking layout in innovative products such as 3D printing and surgical robots, along with the digital orthopedic ecosystem, will create solid technological barriers and open new growth spaces. The overseas business is anticipated to become a strong growth engine as the "JRI + Aikang" dual-brand strategy deepens and product registrations progress. The company is projected to achieve revenues of 1.543 billion, 1.819 billion, and 2.101 billion yuan for 2025-2027, with corresponding growth rates of 14.61%, 17.91%, and 15.50%. Net profits are expected to be 330 million, 385 million, and 438 million yuan, with corresponding growth rates of 20.60%, 16.48%, and 13.84%, maintaining a "buy" rating [3].

Core Viewpoint - The company is progressing normally with its subsidiary, Southern Additive's 3D printing liquid cooling plate project, and is in discussions with potential customers for future collaborations [1] Group 1 - The company announced that it has approved an investment of 50 million yuan for the 3D printing service project, which is set to be executed by September 2025 [1] - The expansion plan for the 3D printing services is currently being implemented as per the company's strategy [1] - The company is actively engaging in business negotiations with relevant customers [1]